A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin™) in mild Alzheimer's disease patients

M. Grundman, E. Capparelli, H. T. Kim, J. C. Morris, Martin Farlow, E. H. Rubin, J. Heidebrink, Ann Hake, G. Ho, A. N. Schultz, K. Schafer, W. Houston, R. Thomas, L. J. Thal

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

A phase 1, randomized, double-blind, placebo-controlled, dose escalation study of the purine derivative, AIT-082 (Neotrofin™, NeoTherapeutics) was conducted in mild Alzheimer's disease (AD) patients to evaluate multiple-dose safety, tolerability, and pharmacokinetics. Possible short-term effects of AIT-082 on cognition and memory were preliminarily investigated. AIT-082 is currently being developed as a potential treatment for Alzheimer's disease and other neurological disorders. Pre-clinical studies indicate that AIT-082 has memory enhancing properties, stimulates neuritogenesis and the production of neurotrophic factors. Patients received an oral dose of AIT-082 or placebo daily for one week. Thirty-six AD patients were divided into three dose cohorts; each dose cohort consisted of twelve patients with 8 patients randomized to AIT-082 and 4 to placebo. The 3 doses of AIT-082 evaluated in this study were 100 mg/day, 500 mg/day, and 2,000 mg/day. There were no serious adverse events at any dose and the drug was well tolerated without significant side effects. AIT-082 was orally and rapidly absorbed, resulting in peak serum concentrations within 2 hours with an elimination half-life of approximately 20 hours. Higher doses resulted in corresponding increases in peak concentrations and areas under the curve (AUC). There was an approximate 2-fold accumulation in AIT-082 with daily dosing (as reflected by the AUC) at steady state. There were no significant differences by treatment arm on the clinical or neuropsychological evaluations. AIT-082 was rapidly absorbed by the oral route with a half-life suitable for dosing once or twice daily. No problems with tolerability or safety were found. AIT-082 appears suitable for testing in larger clinical trials for the treatment of AD and other neurologic disorders.

Original languageEnglish
Pages (from-to)539-553
Number of pages15
JournalLife Sciences
Volume73
Issue number5
DOIs
StatePublished - Jun 20 2003

Fingerprint

Pharmacokinetics
Alzheimer Disease
Placebos
Safety
Nervous System Diseases
Area Under Curve
Half-Life
4-((3-(1,6-dihyro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)benzoic acid
Data storage equipment
Nerve Growth Factors
Cognition
Therapeutics
Clinical Trials

Keywords

  • AIT-082
  • Alzheimer's disease
  • Clinical trial
  • Neotrofin
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology

Cite this

A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin™) in mild Alzheimer's disease patients. / Grundman, M.; Capparelli, E.; Kim, H. T.; Morris, J. C.; Farlow, Martin; Rubin, E. H.; Heidebrink, J.; Hake, Ann; Ho, G.; Schultz, A. N.; Schafer, K.; Houston, W.; Thomas, R.; Thal, L. J.

In: Life Sciences, Vol. 73, No. 5, 20.06.2003, p. 539-553.

Research output: Contribution to journalArticle

Grundman, M, Capparelli, E, Kim, HT, Morris, JC, Farlow, M, Rubin, EH, Heidebrink, J, Hake, A, Ho, G, Schultz, AN, Schafer, K, Houston, W, Thomas, R & Thal, LJ 2003, 'A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin™) in mild Alzheimer's disease patients', Life Sciences, vol. 73, no. 5, pp. 539-553. https://doi.org/10.1016/S0024-3205(03)00320-5
Grundman, M. ; Capparelli, E. ; Kim, H. T. ; Morris, J. C. ; Farlow, Martin ; Rubin, E. H. ; Heidebrink, J. ; Hake, Ann ; Ho, G. ; Schultz, A. N. ; Schafer, K. ; Houston, W. ; Thomas, R. ; Thal, L. J. / A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin™) in mild Alzheimer's disease patients. In: Life Sciences. 2003 ; Vol. 73, No. 5. pp. 539-553.
@article{0f6c42812278463f8e34333c4c3cfcf3,
title = "A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin™) in mild Alzheimer's disease patients",
abstract = "A phase 1, randomized, double-blind, placebo-controlled, dose escalation study of the purine derivative, AIT-082 (Neotrofin™, NeoTherapeutics) was conducted in mild Alzheimer's disease (AD) patients to evaluate multiple-dose safety, tolerability, and pharmacokinetics. Possible short-term effects of AIT-082 on cognition and memory were preliminarily investigated. AIT-082 is currently being developed as a potential treatment for Alzheimer's disease and other neurological disorders. Pre-clinical studies indicate that AIT-082 has memory enhancing properties, stimulates neuritogenesis and the production of neurotrophic factors. Patients received an oral dose of AIT-082 or placebo daily for one week. Thirty-six AD patients were divided into three dose cohorts; each dose cohort consisted of twelve patients with 8 patients randomized to AIT-082 and 4 to placebo. The 3 doses of AIT-082 evaluated in this study were 100 mg/day, 500 mg/day, and 2,000 mg/day. There were no serious adverse events at any dose and the drug was well tolerated without significant side effects. AIT-082 was orally and rapidly absorbed, resulting in peak serum concentrations within 2 hours with an elimination half-life of approximately 20 hours. Higher doses resulted in corresponding increases in peak concentrations and areas under the curve (AUC). There was an approximate 2-fold accumulation in AIT-082 with daily dosing (as reflected by the AUC) at steady state. There were no significant differences by treatment arm on the clinical or neuropsychological evaluations. AIT-082 was rapidly absorbed by the oral route with a half-life suitable for dosing once or twice daily. No problems with tolerability or safety were found. AIT-082 appears suitable for testing in larger clinical trials for the treatment of AD and other neurologic disorders.",
keywords = "AIT-082, Alzheimer's disease, Clinical trial, Neotrofin, Pharmacokinetics",
author = "M. Grundman and E. Capparelli and Kim, {H. T.} and Morris, {J. C.} and Martin Farlow and Rubin, {E. H.} and J. Heidebrink and Ann Hake and G. Ho and Schultz, {A. N.} and K. Schafer and W. Houston and R. Thomas and Thal, {L. J.}",
year = "2003",
month = "6",
day = "20",
doi = "10.1016/S0024-3205(03)00320-5",
language = "English",
volume = "73",
pages = "539--553",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin™) in mild Alzheimer's disease patients

AU - Grundman, M.

AU - Capparelli, E.

AU - Kim, H. T.

AU - Morris, J. C.

AU - Farlow, Martin

AU - Rubin, E. H.

AU - Heidebrink, J.

AU - Hake, Ann

AU - Ho, G.

AU - Schultz, A. N.

AU - Schafer, K.

AU - Houston, W.

AU - Thomas, R.

AU - Thal, L. J.

PY - 2003/6/20

Y1 - 2003/6/20

N2 - A phase 1, randomized, double-blind, placebo-controlled, dose escalation study of the purine derivative, AIT-082 (Neotrofin™, NeoTherapeutics) was conducted in mild Alzheimer's disease (AD) patients to evaluate multiple-dose safety, tolerability, and pharmacokinetics. Possible short-term effects of AIT-082 on cognition and memory were preliminarily investigated. AIT-082 is currently being developed as a potential treatment for Alzheimer's disease and other neurological disorders. Pre-clinical studies indicate that AIT-082 has memory enhancing properties, stimulates neuritogenesis and the production of neurotrophic factors. Patients received an oral dose of AIT-082 or placebo daily for one week. Thirty-six AD patients were divided into three dose cohorts; each dose cohort consisted of twelve patients with 8 patients randomized to AIT-082 and 4 to placebo. The 3 doses of AIT-082 evaluated in this study were 100 mg/day, 500 mg/day, and 2,000 mg/day. There were no serious adverse events at any dose and the drug was well tolerated without significant side effects. AIT-082 was orally and rapidly absorbed, resulting in peak serum concentrations within 2 hours with an elimination half-life of approximately 20 hours. Higher doses resulted in corresponding increases in peak concentrations and areas under the curve (AUC). There was an approximate 2-fold accumulation in AIT-082 with daily dosing (as reflected by the AUC) at steady state. There were no significant differences by treatment arm on the clinical or neuropsychological evaluations. AIT-082 was rapidly absorbed by the oral route with a half-life suitable for dosing once or twice daily. No problems with tolerability or safety were found. AIT-082 appears suitable for testing in larger clinical trials for the treatment of AD and other neurologic disorders.

AB - A phase 1, randomized, double-blind, placebo-controlled, dose escalation study of the purine derivative, AIT-082 (Neotrofin™, NeoTherapeutics) was conducted in mild Alzheimer's disease (AD) patients to evaluate multiple-dose safety, tolerability, and pharmacokinetics. Possible short-term effects of AIT-082 on cognition and memory were preliminarily investigated. AIT-082 is currently being developed as a potential treatment for Alzheimer's disease and other neurological disorders. Pre-clinical studies indicate that AIT-082 has memory enhancing properties, stimulates neuritogenesis and the production of neurotrophic factors. Patients received an oral dose of AIT-082 or placebo daily for one week. Thirty-six AD patients were divided into three dose cohorts; each dose cohort consisted of twelve patients with 8 patients randomized to AIT-082 and 4 to placebo. The 3 doses of AIT-082 evaluated in this study were 100 mg/day, 500 mg/day, and 2,000 mg/day. There were no serious adverse events at any dose and the drug was well tolerated without significant side effects. AIT-082 was orally and rapidly absorbed, resulting in peak serum concentrations within 2 hours with an elimination half-life of approximately 20 hours. Higher doses resulted in corresponding increases in peak concentrations and areas under the curve (AUC). There was an approximate 2-fold accumulation in AIT-082 with daily dosing (as reflected by the AUC) at steady state. There were no significant differences by treatment arm on the clinical or neuropsychological evaluations. AIT-082 was rapidly absorbed by the oral route with a half-life suitable for dosing once or twice daily. No problems with tolerability or safety were found. AIT-082 appears suitable for testing in larger clinical trials for the treatment of AD and other neurologic disorders.

KW - AIT-082

KW - Alzheimer's disease

KW - Clinical trial

KW - Neotrofin

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0038631907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038631907&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(03)00320-5

DO - 10.1016/S0024-3205(03)00320-5

M3 - Article

C2 - 12770610

AN - SCOPUS:0038631907

VL - 73

SP - 539

EP - 553

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 5

ER -